Retinal Disease Therapeutics Market Size, Share, Growth Analysis, By Type(Macular degeneration, Diabetic retinopathy, others), By Dosage forms(Gels, Eye solutions, Capsules & Tablets, Eye drops), By Distribution Channel(Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By Region - Industry Forecast 2024-2031

Retinal Disease Therapeutics Market Driver

• Increased Prevalence of Disorders Related to the Eyes
  The prevalence of eye-related illnesses is rising, particularly in developed countries, which will drive the global market for retinal medications over the forecast period. According to an update from the American Academy of Ophthalmology, approximately 93 million people worldwide had diabetic retinopathy in 2016, with 4.2 million of those patients being Americans. According to the NCBI, by 2040, there will be 14.9 to 21.5 million people with early AMD and 3.9 to 4.8 million people with late AMD in Europe. Increasing health education activities regarding eye disorders to seek early treatment and prevent vision impairment in developing regions are also expected to fuel the global retinal disease therapeutics market growth during the forecast period.

Growing Initiatives for Retinal Diseases Awareness

Globally a number of programmes have been launched to raise knowledge of retinal disease diagnosis and treatment options. The mission of the International Centre for Eye Health is to raise public knowledge of eye health issues and available treatments. For the past six years, the World Glaucoma Association has organized the World Glaucoma Congress to promote debate of glaucoma treatment breakthroughs. The Macular Degeneration Association, Inc. hosts seminars every month in a variety of locations to improve the uptake of age-related macular degeneration treatments (AMD). These activities are expected to promote the use of different treatment modalities, which is projected to drive the retinal disease therapeutics market expansion.

Retinal Disease Therapeutics Market Restraint

Higher Cost Associated with the Treatment of Retinal Diseases

• Growth of the global market may be hampered by the high cost of retina treatment therapies, patient complaints of short-term side effects, and long-term consequences such as infection and inflammation following laser eye surgery. Additionally, risks such as unintentional scleral perforation may arise during surgical techniques such pneumatic retinopexy, which may have an impact on patient preferences and restrain growth of the global market. Poor healthcare infrastructure in emerging nations is also hampering the retinal disease therapeutics market.